USE FIRST20 TO GET 20% OFF ON YOUR FIRST ORDER
✓
CJC-1295 (No DAC) also known as: Modified GRF 1-29, Mod GRF(1-29), CJC-1293 (closely related).
What is it?
CJC-1295 (No DAC) is a short-acting compound that supports the body’s natural growth hormone release by binding to the relevant receptor in the pituitary gland. It is a research tool for studying the growth hormone system.
—
Key Benefits (from research)
– Works with your body’s natural rhythms — Research confirms it preserves the natural pulsatile pattern of growth hormone release, unlike direct growth hormone injections.
– Raises GH and IGF-1 levels – Studies in healthy adults confirm measurable increases in both growth hormone and IGF-1, the downstream growth signal.
– Body composition research – Elevated GH axis activity is linked to reduced body fat and more lean tissue in research models.
– High receptor affinity – The compound’s modified structure gives it stronger binding to the pituitary receptor and greater resistance to breakdown than the natural hormone.
– Ageing research – Identified in gerontology literature as a research tool for the age-related decline in growth hormone output. Well-characterised pharmacologically metabolism and detection have been studied in detail, including validated methods used in anti-doping research.
—
Quick Q&A
What is CJC-1295 No DAC used for in research?
It is used to study how growth hormone is released in pulses, and what effect increased GH and IGF-1 have on body composition and the ageing process.
Is it approved for people?
No it is sold for laboratory research only.
Important Notice
Sold for laboratory research only. Not for human use. Must be 18+.
More information
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic analogue of GHRH. The DAC modification enables covalent binding to serum albumin, extending the biological half-life to approximately 8 days. This allows for sustained GH and IGF-1 elevation in preclinical research models. For laboratory research use only.
